A new breast cancer drug trialled at King's College London is to be blocked from routine NHS access under draft guidance issued by health watchdog NICE.

NICE say that Kadcyla can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay - despite it extending women's lives by almost six months. Patients will be able to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug.

But the decision, if made final later this year, would mean the drug would not be recommended for routine use in England on the NHS and women would have to rely on their doctors' successful application to the Cancer Drugs Fund.

The men's health charity Orchid has launched a confidential free phone National Male Cancer Helpline to answer any questions men might have about the disease and its symptoms.

Specialist nurses will staff the line Monday to Wednesday from 10am-6pm on 0808 802 0010.

Testicular cancer is the most common cancer in men aged between 15-45 years, with around 2,200-2,300 men being diagnosed each year. Awareness of the disease has improved in the past 5 years, but these findings show that vital life-saving health messages still aren't reaching the vast majority of men.

We're calling on London's busy men to take a few minutes to learn about how to carry out simple self checks and to recognise the early warning signs and symptoms regardless of their work obligations and pace of life. Getting an early diagnosis is vital - if caught early, testicular cancer can be 98% curable.